Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Indivior on Demerger from Reckitt Benckiser

November 17, 2014

LONDON, 17 November, 2014 — Covington is advising Indivior, formerly RB Pharmaceuticals, in the demerger transaction announced today from Reckitt Benckiser, a global consumer products company. The demerger is subject to the approval of RB shareholders.

Indivior PLC will be a specialty pharmaceutical company focused on the treatment of addiction and closely related mental health disorders, with net revenues of $1.2 billion. The company intends to apply for admission of all of its ordinary shares to the premium listing segment of the Official List of the UK Listing Authority and to trading on the main market for listed securities of London Stock Exchange plc.

The cross-Atlantic Covington team was led by partners Scott Smith, Simon Amies, Peter Laveran, Daniel Pavin, Hilary Prescott and Eric Blanchard and special counsel Brian Rosenzweig.

Share this article: